Logo

PharmaShots Weekly Snapshot (April 01-05, 2019)

Share this

PharmaShots Weekly Snapshot (April 01-05, 2019)

?Amazon Launches Alexa’s Health Services for Managing Health and Handling Patients Data

Published: April 05, 2019 | Tags: Amazon, Launches, Alexa, Health Services, Managing Health, Handling Patients Data

Roivant Launches Cytovant Sciences to Collaborates with Medigene for the Development of Cellular Therapies in Asia

Published: April 05, 2019 | Tags: Roivant, Launches, Cytovant Sciences, Collaborates, Medigene, Development, Cellular Therapies, Asia

? ?Abbott Signs a Non-Exclusive License Agreement with Banyan Biomarkers for its Traumatic Brain Injury (TBI) Blood Biomarkers

Published: April 05, 2019 | Tags: Abbott, Signs, Non-Exclusive, License Agreement, Banyan, Traumatic Brain Injury, TBI, Biomarkers

Myriad Expands its Companion Diagnostic Collaboration with AstraZeneca and Merck

Published: April 05, 2019 | Tags: Myriad, Expands, Companion Diagnostic, Collaboration, AstraZeneca, Merck

?Oncology Venture Signs an Exclusive Option Agreement to In-License Commercialization Rights for R-Pharm’s Ixempra (ixabepilone) in EU

Published: April 05, 2019 | Tags: Oncology Venture,Signs, Exclusive, Option, Agreement, In-License, Commercialization, Rights, R-Pharm, Ixempra, ixabepilone, EU, Metastaic Breast Cancer

?AstraZeneca and the US NIAID Report Results of Fasenra (benralizumab) in P-II Study for Hypereosinophilic Syndromes (HES)

Published: April 04, 2019 | Tags: AstraZeneca, Fasenra, benralizumab, Receives, FDA, Approval, Hypereosinophilic Syndromes, HES

Genmab and Janssen Biotech Report Initiation of P-III MMY3021 Study for Darzalex (daratumumab) in Multiple Myeloma

Published: April 04, 2019 | Tags:Genmab, Janssen Biotech, Report, Initiation, P-III, MMY3021 Study, Daratumumab, Multiple Myeloma

Editas Medicine Signs a Research and Cross-Licensing Agreement with BlueRock Therapeutics for their Technologies

Published: April 04, 2019 | Tags: Editas, Medicine, Signs, Research, Cross-Licensing Agreement, BlueRock Therapeutics, Combine; Genome Editing, Cell Therapy Technology

Fresenius Kabi’s Idacio (adalimumab, biosimilar) Receives EU’s Marketing Approval in Rheumatology, Gastroenterology and Dermatology

Published: April 04, 2019 | Tags: Fresenius Kabi, Idacio, adalimumab, biosimilar, Receives, EU, Marketing Approval, Rheumatology, Gastroenterology, Dermatology

?Liquidia Reports Results of LIQ861 in P-III INSPIRE Trial in Patients with Pulmonary Arterial Hypertension (PAH)

Published: April 04, 2019 | Tags: Liquidia, Reports, Results, LIQ861, P-III, INSPIRE trial, Patients, Pulmonary Arterial Hypertension, PAH

Channel Medsystems’ Cerene Cryotherapy Device Receives FDA’s Approval for Heavy Menstrual Bleeding

Published: April 03, 2019 | Tags: Channel Medsystems, Cerene Cryotherapy Device, Receives, FDA, Approval, Heavy Menstrual Bleeding

?Dermelix Collaborates with EspeRare to Co-develop and Commercialize DMX-101 for XLHED

Published: April 03, 2019 | Tags: Dermelix, Collaborates, EspeRare, Co-develop, Commercialize, DMX-101, XLHED

?Encore Dermatology to Acquire US Commercialization Rights for Dr. Reddy’s Three Dermatology Products

Published: April 03, 2019 | Tags: Encore Dermatology, Acquire, US, Commercialization Rights, Dr. Reddy, Three, Dermatology, Products

?Astellas Signs a Research and License Agreement with Xencor for Bispecific Antibody Program in Oncology

Published: April 03, 2019 | Tags: Astellas, Signs, Research Agreement, Xencor, Novel, Bispecific, Antibody,Program

Allergan and Molecular Partners Report Result of Abicipar pegol in P-III MAPLE Study for Neovascular Macular Degeneration (nAMD)?

Published: April 03, 2019 | Tags: Allergan, Molecular Partners, Report, Result, Abicipar pegol, P-III, MAPLE Study, Neovascular Macular Degeneration, nAMD

Sangamo Therapeutics Signs an Option Agreement with Brammer Bio for its AAV Manufacturing Facility

Published: April 02, 2019 | Tags: Sangamo Therapeutics, Signs, Option, Agreement, Brammer Bio, AAV, Manufacturing, Facility

Novartis’ Cosentyx (secukinumab) Receives NMPA’s (CFDA) Approval for Patients with Plaque Psoriasis in Adults

Published: April 02, 2019 | Tags: Novartis, Cosentyx, secukinumab, Receives, NMPA, CFDA, Approval, Patients, Psoriasis

Merck’s Keytruda (pembrolizumab) + Chemotherapy Receive NMPA’s (CFDA) Approval for 1L Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

Published: April 02, 2019 | Tags: Merck; Keytruda; pembrolizumab; Chemotherapy; Receive; NMPA; CFDA; Approval; 1L; Metastatic; Non-Squamous; Non-Small Cell Lung Cancer; NSCLC

AveXis to Purchase Biologics Manufacturing Facility in Colorado

Published: April 02, 2019 | Tags: AveXis, Purchase, Biologics, Therapy, Manufacturing Facility, Longmont, Colorado

?VistaGen Therapeutics Reports Positive Results of PH94B in P-III study for Social Anxiety Disorder (SAD)

Published: April 02, 2019 | Tags: VistaGen; Reports; Positive; Results; PH94B; P-III; Social Anxiety Disorder; SAD

?Roche Reports Result of Ipatasertib + Tecentriq (atezolizumab) in P-Ib Study for 1L Patients with Advanced Triple-Negative Breast Cancer (TNBC)

Published: April 01, 2019 | Tags: Roche, Reports, Results, Ipatasertib, Tecentriq, atezolizumab, P-Ib, Study, 1L Patients, Advanced Triple-Negative Breast Cancer, TNBC

Boehringer Ingelheim (BI) to Acquire ICD Therapeutics for its MacroDel Delivery Technology

Published: April 01, 2019 | Tags: Boehringer Ingelheim, Acquires, ICD Therapeutics, Novel MacroDel Delivery Technology

?Novartis to Acquire IFM Tre for its Clinical and Preclinical Portfolio of NLRP3 Inhibitors for $1.5B

Published: April 01, 2019 | Tags: Novartis, Acquire, IFM Tre, NLRP3 Inhibitors, Portfolio

?Bluebird Bio’s Zynteglo Receives CHMP’s Positive Opinion for Conditional Marketing for Patients with Transfusion-Dependent ß-Thalassemia (TDT) without ß0/ß0 Genotype

Published: April 01, 2019 | Tags: Bluebird Bio, Zynteglo, Receives, CHMP, Positive Opinion, Conditional Marketing, Patients, Transfusion-Dependent ß-Thalassemia, TDT, Without, ß0/ß0 Genotype

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions